Enlivex Therapeutics (NASDAQ:ENLV) PT Lowered to $7.00

Enlivex Therapeutics (NASDAQ:ENLV) had its price objective lowered by equities research analysts at HC Wainwright from $12.00 to $7.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 343.04% from the company’s previous close. HC Wainwright also issued estimates for Enlivex Therapeutics’ FY2025 earnings at ($0.55) EPS.

Enlivex Therapeutics Price Performance

Shares of ENLV opened at $1.58 on Friday. The firm has a market cap of $29.34 million, a PE ratio of -1.01 and a beta of 1.02. The stock’s fifty day moving average price is $3.46 and its two-hundred day moving average price is $2.54. Enlivex Therapeutics has a 1 year low of $1.20 and a 1 year high of $4.59.

Institutional Trading of Enlivex Therapeutics

Hedge funds have recently made changes to their positions in the company. Jane Street Group LLC raised its stake in shares of Enlivex Therapeutics by 89.6% in the first quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock valued at $294,000 after buying an additional 24,807 shares during the period. UBS Group AG raised its stake in shares of Enlivex Therapeutics by 73.4% in the third quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after buying an additional 13,490 shares during the period. Goldman Sachs Group Inc. purchased a new position in shares of Enlivex Therapeutics in the first quarter valued at $68,000. Finally, Bank of America Corp DE grew its position in shares of Enlivex Therapeutics by 87.0% in the first quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock valued at $34,000 after purchasing an additional 2,867 shares in the last quarter. 1.02% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.